Ποια είναι η τιμή για TMS Co., Ltd. (4891)

Η τιμή για TMS Co., Ltd. (4891) είναι $0.72420509

Ποια είναι η κεφαλαιοποίηση αγοράς για TMS Co., Ltd. (4891)

Η κεφαλαιοποίηση αγοράς για TMS Co., Ltd. (4891) είναι $33.00M

TMS Co., Ltd. (4891) Τιμή και Κεφαλαιοποίηση Αγοράς

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.

Η τιμή για 4891	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$116,327 $33.00M	NVDA	$5.301T	+16,062,602.78%
$101,690 $33.00M	AAPL	$4.634T	+14,041,458.10%
$90,917.22 $33.00M	GOOG	$4.143T	+12,553,970.25%
$78,768.35 $33.00M	MSFT	$3.589T	+10,876,425.87%
$62,695.39 $33.00M	AMZN	$2.857T	+8,657,032.55%

Η τιμή για 4891

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$116,327 $33.00M